BiotechTube
Dialectic Therapeutics

Dialectic Therapeutics

Dallas, United States· Est.
dtsciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Dialectic Therapeutics is a private, preclinical-to-clinical stage biotech developing novel cancer therapies based on its Antiapoptotic Protein Targeted Degradation (APTaD™) platform. Its lead candidate, DT2216, is a BCL-XL degrader currently in Phase 1/2 trials for Fibrolamellar Carcinoma and Platinum-Resistant Ovarian Cancer. The company is led by a team with strong scientific, clinical, and commercial biotech experience, including co-founder John Harkey Jr., who previously co-founded and led AveXis to an $8.7bn acquisition. Dialectic operates as a virtual company, leveraging research partnerships with academic institutions.

Oncology

Technology Platform

Antiapoptotic Protein Targeted Degradation (APTaD™) platform, a heterobifunctional small molecule approach for targeted protein degradation, specifically focused on eliminating anti-apoptotic proteins that drive cancer cell survival.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

Validating the APTaD™ platform with DT2216 could unlock a broad pipeline of novel degraders targeting other 'undruggable' anti-apoptotic and cancer-related proteins.
The initial focus on high-unmet-need, niche oncology indications (e.g., Fibrolamellar Carcinoma) offers potential for accelerated regulatory pathways and orphan drug benefits, de-risking the platform for expansion into larger solid tumor markets.

Risk Factors

The company faces significant clinical development risk, as the Phase 1/2 trials for its lead asset must confirm promising preclinical safety (especially reduced platelet toxicity) and show efficacy.
As a private, pre-revenue firm, it is also exposed to financing risk and operates in the highly competitive and scientifically challenging field of targeted protein degradation.

Competitive Landscape

Dialectic competes in the rapidly evolving targeted protein degradation space against well-funded public companies like Arvinas, Kymera Therapeutics, and Nurix Therapeutics, which have broader platforms and advanced pipelines. Its specific focus on anti-apoptotic proteins (BCL-XL) also places it in competition with developers of BH3 mimetics (e.g., AbbVie/Venclexta) and other apoptosis-targeting therapies, where demonstrating superior safety or efficacy is critical.

More companies in Oncology (General) →More companies in United States →